Hosted on MSN25d
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears
Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go before the patents protecting the original version expire. Keytruda ...
Seeking Alpha1mon
Merck rival Summit draws new buy from Truist on deal prospects
Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...
Wall Street Journal1mon
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi 2269-0.22%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-0.50%decrease; red down pointing triangle & Co. for half a billion dollars ...